Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech industry report

Frost & Sullivan Gut Microbiota White Book

Analysis based on 7 articles · First reported Sep 15, 2026 · Last updated Sep 16, 2026

Sentiment
15
Attention
1
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The report is a research publication rather than a transactional event, so its direct market impact is limited and mainly informational for investors tracking the gut microbiota and live biotherapeutics space. It may modestly raise investor attention to microbiome drug developers and probiotic health product makers in China, the United States, Europe, and Canada, but no immediate price-moving action is involved.

biotechnology pharmaceuticals healthcare

Frost & Sullivan published the White Book on the Current Landscape and Future Trends of the Gut Microbiota Industry, a comprehensive research report on the global gut microbiota sector. The report covers the relationship between gut microbiota and health and disease, the current landscape of gut microbiota drug development, market analysis of health supplements, and future trends. It highlights Live Biotherapeutic Products (LBPs), biologics derived from live organisms intended to prevent, treat, or cure human diseases, which the United States — Food and Drug Administration defines as distinct from conventional probiotics and subject to pharmaceutical development standards. Clinical trials for gut microbiota-based therapeutics are concentrated in China, the United States, Europe, and Canada, with fecal microbiota transplantation (FMT) accounting for roughly 44.2% of active pipelines and single-strain microbial therapeutics about 30%. The report notes that Chinese gut microbiota enterprises are expanding globally, supported by market demand, rising investment, and government policies in China, the United States, and the European Union. China reportedly ranks first globally in microbiota-related patent applications with 33% of the total. The report also outlines the industry value chain from upstream diagnostic platforms and strain resources to midstream therapeutics and health products and downstream clinical institutions and consumers, and expects strong growth momentum as regulatory frameworks improve and business models evolve toward personalized health solutions.

70 Frost & Sullivan published white book
40 China issued supportive policies
35 United States issued supportive policies
35 European Union issued supportive policies
30 United States — Food and Drug Administration defined live biotherapeutic products
priv
Frost & Sullivan authored and published the white book, positioning itself as a leading research and consulting voice on the gut microbiota industry and strengthening its franchise in healthcare and advanced-technology research.
Importance 100.0 Sentiment 10.0
cnt
China is highlighted as a leading market for gut microbiota clinical trials and patent applications, with supportive government policies and expanding Chinese enterprises entering global markets.
Importance 55.0 Sentiment 15.0
govactor
The United States — Food and Drug Administration is cited for its definition of Live Biotherapeutic Products as biologics distinct from conventional probiotics, a regulatory framework that shapes development standards for microbiome therapeutics.
Importance 40.0 Sentiment 5.0
cnt
The United States is noted as a major hub for gut microbiota clinical trials and for government initiatives and supportive policies promoting research and industrial development in the sector.
Importance 40.0 Sentiment 10.0
alliance
The European Union is cited among governments issuing supportive policies and hosting clinical trials for gut microbiota-based therapeutics, contributing to the industry's regulatory and research momentum.
Importance 35.0 Sentiment 10.0
cnt
Canada is listed as one of the primary regions where clinical trials for gut microbiota-based therapeutics are concentrated, giving it a modest role in the global development landscape.
Importance 25.0 Sentiment 5.0
Frost & Sullivan related ↔ China
China strategic rival ↔ United States China views the United States as a strategic rival, actively competing across economic, technological, and military doma
China related ↔ European Union
China related ↔ Canada
United States trade rivals ↔ Canada The United States views Canada as a key defense partner but also a trade rival, having imposed tariffs and declined to r
European Union related ↔ Canada
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.